{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:04:37Z","timestamp":1777539877746,"version":"3.51.4"},"reference-count":6,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction:<\/jats:title>\n                  <jats:p>This chart review utilizes readmission rates and mean time to readmission as markers of drug efficacy to compare different categories of long-acting injectable antipsychotics (LAIAs), antipsychotic polypharmacy, and clozapine to oral antipsychotic monotherapy (OM) at a state psychiatric hospital in Oregon (Oregon State Hospital).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Charts were reviewed for patients discharged between October 20, 2011, and September 23, 2015, with a diagnosis of schizophrenia spectrum or mood disorder. Admission dates, discharge dates, and discharge antipsychotics were reviewed for each patient dating back to 1991. Discharge antipsychotics were categorized into groupings of LAIAs, antipsychotic polypharmacy, and clozapine and compared with OM to assess readmission data within 1, 3, and 5 years of discharge. The primary end point was readmission rate, measured as a percentage, and the secondary end point was mean time to readmission (MTR), measured in days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Of 1088 patients reviewed, there were 2031 patient discharges associated with antipsychotic agents and 1258 readmissions. Patients discharged on LAIA monotherapy or clozapine generally had a lower readmission rate, and patients discharged on antipsychotic polypharmacy generally had a higher readmission rate. Statistical significance for these findings varied over time frames and subgroup analyses. The most notable finding for the secondary end point was a significantly shorter MTR for patients discharged on clozapine for all diagnoses and the subgroup analysis of schizoaffective disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion:<\/jats:title>\n                  <jats:p>These results are only a reflection of the patient population at this hospital, and additional reviews at other facilities with different patient characteristics could clarify applicability to other patient populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2017.05.124","type":"journal-article","created":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T21:31:25Z","timestamp":1493674285000},"page":"124-130","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-226X","authenticated-orcid":false,"given":"Joni","family":"Baker","sequence":"first","affiliation":[{"name":"(Corresponding author) Pharmacy Resident, Oregon State Hospital, Salem, Oregon, jbaker4@samford.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-3735","authenticated-orcid":false,"given":"Cydreese","family":"Aebi","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Manager and Residency Program Director, Oregon State Hospital, Salem, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"1","key":"2020060307261022100_i2168-9709-7-3-124-b01","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"2020060307261022100_i2168-9709-7-3-124-b02","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1471-244X-13-221","article-title":"Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis","volume":"13","author":"Lafeuille","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"6","key":"2020060307261022100_i2168-9709-7-3-124-b03","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/ajp.156.6.863","article-title":"Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine","volume":"156","author":"Conley","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2020060307261022100_i2168-9709-7-3-124-b04","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.psychres.2011.04.004","article-title":"Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine","volume":"188","author":"Werneck","year":"2011","journal-title":"Psychiatry Res"},{"issue":"2","key":"2020060307261022100_i2168-9709-7-3-124-b05","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/schbul\/sbu067","article-title":"Comparison of SGA oral medications and long-acting injectable SGA: the PROACTIVE study","volume":"41","author":"Buckley","year":"2015","journal-title":"Schizophr Bull"},{"key":"2020060307261022100_i2168-9709-7-3-124-b06","article-title":"CLOZARIL (clozapine) tablet [Internet]. 1989 [rev. 2015 Sept; cited 2016 Jun 20]","author":"Novartis Pharmaceutical Corporation","journal-title":"DailyMed"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/3\/124\/2096106\/mhc_2017_05_124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/3\/124\/2096106\/mhc_2017_05_124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:20:28Z","timestamp":1731687628000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/3\/article-p124.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.05.124","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,1]]}}}